MedTrace Logo

Fimasartan Blood Pressure Lowering After Acute Stroke

NCT03231293 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1035

Last updated 2019-11-04

No results posted yet for this study

Summary

This study evaluates the effectiveness of fimasartan-based antihypertensive treatment and prognosis in post-acute phase of ischemic stroke or transient ischemic attack patients. All participants will receive fimasartan, and the investigators will follow them up for 6 months.

Conditions

Sponsors & Collaborators

  • Boryung Pharmaceutical Co., Ltd

    lead INDUSTRY

Principal Investigators

  • Myung Sook Hong · Boryung Pharmaceutical Co., Ltd

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-28
Primary Completion
2018-11-02
Completion
2019-04-05

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03231293 on ClinicalTrials.gov